论文部分内容阅读
目的探讨尼莫地平对脑卒中后认知功能障碍的改善作用。方法将145例卒中后认知功能障碍患者随机分为两组,对照组常规治疗原发病、康复训练及心理支持;治疗组在此基础上同时合并使用尼莫地平片30 mg,3次/d,各组患者观察治疗至4周末。在治疗前及治疗后4周进行蒙特利尔认知评估量表(Montreal Cognitive Assessment,MoCA)评分。结果两组患者治疗前采用MoCA评分,差异无统计学意义(P>0.05);对照组治疗4周后MoCA评分有所改善,但与治疗前对比差异无统计学意义(P>0.05),治疗组治疗4周后MoCA评分明显改善,表现在记忆力、视空间与执行功能及总分方面差异有统计学意义(P<0.05)。结论尼莫地平治疗脑卒中后认知功能障碍的疗效确切。
Objective To investigate the effect of nimodipine on cognitive dysfunction after stroke. Methods 145 patients with cognitive dysfunction after stroke were randomly divided into two groups. The control group received routine treatment of primary disease, rehabilitation training and psychological support. On the basis of this study, the treatment group was treated with 30 mg nimodipine 3 times / d, the observation and treatment of patients in each group to 4 weeks. The Montreal Cognitive Assessment (MoCA) score was taken before treatment and 4 weeks after treatment. Results MoCA score was used before treatment in both groups, with no significant difference (P> 0.05). The MoCA score improved in the control group after 4 weeks of treatment, but there was no significant difference between before and after treatment (P> 0.05) After 4 weeks of treatment, MoCA score improved significantly, showing significant differences in memory, visual function, and total score (P <0.05). Conclusion Nimodipine is effective in treating cognitive dysfunction after stroke.